The AI landscape doesn't move in one direction — it lurches. Some techniques leap from experiment to table stakes in a single quarter; others stall against regulatory walls, technical ceilings, or organisational inertia that no amount of hype can dislodge. Knowing which is which is the hard part. The State of Play cuts through the noise with a rigorously maintained index of AI techniques across every major business domain — classified by maturity, evidenced by real-world adoption, and updated daily so you always know where you stand relative to the field. Stop guessing. Start knowing.
A daily newsletter distilling the past two weeks of movement in a domain or two — delivered to your inbox while the index updates in the background.
Each dot marks the weighted maturity of practices within a domain — hover for a brief summary, click for more detail
AI-enhanced surgical robots that augment surgeon capabilities with precision guidance, tremor compensation, and visualisation. Includes da Vinci-style teleoperated systems with AI overlay; distinct from semi-autonomous surgery which performs procedure steps independently.
Surgeon-assisted surgical robotics is a mature, proven practice whose central question has shifted from clinical validation to economic and geographic accessibility. Teleoperated platforms -- led by Intuitive's da Vinci and now challenged by Medtronic's Hugo RAS and others -- augment surgeon precision through tremor filtration, motion scaling, and 3D visualisation, with over 20 million cumulative patient procedures confirming clinical efficacy across urology, general surgery, gynaecology, and colorectal specialties. The ecosystem has entered genuine multi-vendor competition: peer-reviewed head-to-head studies show clinical parity between Hugo RAS and da Vinci, and the fifth-generation da Vinci 5 introduces force feedback that addresses a longstanding limitation. Q2 2026 adoption data shows 847,000 cumulative da Vinci procedures and 11,710 systems in the installed base (12% YoY growth), with 468 new systems placed in Q2 alone (18% YoY increase), 246 of which are da Vinci 5 units, reflecting accelerating fifth-generation penetration. Yet adoption remains concentrated and performance gains increasingly questioned: robotic-assisted surgery accounts for roughly 5% of U.S. procedures and under 1% globally, constrained by capital costs of $1.5--2.5 million per system, inconsistent cost-effectiveness evidence, training standardization gaps, and device reliability issues that continue to trigger regulatory recalls. Critically, recent high-quality evidence shows robotics does not universally improve outcomes—a 949k-patient bariatric surgery registry found higher 30-day serious adverse events with robotic assistance vs laparoscopy, and meta-analysis of hysterectomy procedures shows no clinical superiority despite significantly higher costs. The practice is well past the question of whether it works; what remains unresolved is for which procedures and patient populations it justifiably works, given persistent geographic disparities, cost barriers, and evidence of limited net benefit in already-standardized operations.
Intuitive Surgical's da Vinci platform maintains 70% installed base dominance with 11,710 systems (Q2 2026) and 847,000 cumulative procedures showing 15% year-over-year growth. Q2 metrics confirm 468 new placements (246 da Vinci 5 units, 37% YoY increase), with fifth-generation adoption expanding from academic centers into ambulatory surgery centers and regional health systems. Institutional deployments continue: Duly Health deployed da Vinci 5 in Illinois ASC (June 2026) establishing 200–300 procedure/year profitability threshold; Sunshine Coast University Hospital (Australia) documented 5-to-1 night reductions in urology LOS and 10-to-1 night reductions in hysterectomy; NYC Health + Hospitals reached 20,000+ cumulative procedures across 19 robots at 10 hospitals with 100+ trained surgeons. South Korea market demonstrates regional maturity: robotic-assisted procedures grew from 6% (2019) to 16% (2025) of all surgeries, with 85,000 annual da Vinci procedures and 46% lower 30-day mortality vs open surgery.
Competitive ecosystem maturation accelerated through July–August 2026 with landmark FDA action: Johnson & Johnson received FDA De Novo authorization (July 22, 2026) for the OTTAVA Robotic Surgical System, a table-integrated soft-tissue platform approved for 10 general surgery indications (gastric bypass, gastrectomy, cholecystectomy, splenectomy, and others). OTTAVA's FDA clearance represents the first new major device category in two decades and signals the end of da Vinci's soft-tissue monopoly, establishing a three-vendor competitive ecosystem. Medtronic's Hugo RAS platform achieved regulatory validation through the Expand URO trial (137 patients across 6 U.S. centers, July 2026), demonstrating 98.5% surgical success with safety endpoints met favorably (prostatectomy 3.7% grade III+ complications, nephrectomy 1.9%, cystectomy 17.9%), clinically validating platform parity with da Vinci. High-quality phase 3 RCT evidence (PORTAL trial, 7 Chinese hospitals, 268 patients) now documents robotic pancreatoduodenectomy achieves non-inferiority for functional recovery (12.1 vs 16.0 days) with reduced morbidity (31.1% vs 36.1%) compared to open approach, though with longer operative time and higher cost—establishing oncologic benefit at production-volume credentialed centers. Systematic learning-curve analysis across 24 studies (>3,500 rectal cancer procedures) confirms robotic surgery decouples speed from safety, achieving conversion rates of 1.0–3.2% even in early learning phases vs 12.2–15.0% laparoscopic baseline, with oncological quality (TME, CRM, nodal yield) stable throughout. A 10-year institutional cohort (Bielefeld, 239 procedures, propensity-matched) demonstrated robotic rectal resection achieves 2.7% conversion (vs 15.1% laparoscopic) and −4.72 day shorter post-operative stay. Third-generation competitive entrant SS Innovations (SSi Mantra) now operates 200+ systems across 12,000+ procedures in 170 surgical indications globally, pursuing affordability and telesurgery to expand adoption in cost-conscious healthcare systems.
Despite clinical advancement and ecosystem maturation, critical structural barriers to broader adoption remain entrenched and show no signs of resolution. A landmark reimbursement analysis by domain expert Dwight Meglan (25+ years surgical robotics) documents that neither Medicare nor commercial payers provide payment premium for robotic vs laparoscopic surgery despite 10 million+ cumulative U.S. procedures—a zero-payment barrier affecting all surgeon-assisted platforms and indicating reimbursement policy as the primary structural constraint to volume growth. French healthcare economic analysis documents institutional-scale adoption failure: public hospitals absorb full capital costs (€1–2.5M) and consumables while receiving conventional surgery reimbursement, creating negative unit economics absent territorial consolidation and shared services—a finding directly mirrored in cost-effectiveness assessments across high-income healthcare systems. Negative outcome evidence continues to emerge in procedures previously assumed to benefit from robotics: 949,570-patient bariatric registry found robotic-assisted surgery associated with higher 30-day serious adverse events vs conventional laparoscopy (2.4–15.2 per 1,000 excess risk); meta-analysis of robotic hysterectomy found no clinical advantage over laparoscopy despite $1,600–2,500 higher per-case cost; Lancet RCT (308 patients) found no differences in functional outcomes comparing robotic vs open radical prostatectomy. Device reliability concerns persist at scale: FDA Class II recalls through August 2026 affected 219 da Vinci systems (software errors allowing faulty instrument arms), Health Canada recalls affected multiple Hugo RAS consoles (power supply, communication errors), and Intuitive Surgical settlement of ~3,000 product liability claims ($67M) with 93+ active lawsuits documents sustained post-market safety concerns. Training standardization gaps remain unresolved despite 100% of U.S. general surgery residencies providing robotic exposure: consensus from Robotic Surgery Education Working Group identifies lack of standardized proficiency assessment and institutional variability. Geographic access disparities persist: UK data show severe NHS inequity (London 28 systems vs South West 6); 70,000 procedures in England 2023/24 against government targets of 500,000 by 2035. Adoption plateau is now evident: U.S. procedure growth decelerated to 12% in H1 2026 (from 14% prior year) due to ACA subsidy expiration and market saturation in reimbursement-favorable indications; bariatric procedures declined as GLP-1 obesity drugs reduce surgical demand. These converging constraints—zero payment premium, negative unit economics in hospital budgets, limited evidence of net benefit in standardized procedures, unresolved device reliability, and geographic access disparities—explain why adoption remains confined to resource-rich healthcare systems at 5% U.S. procedural penetration, 2% in Europe, under 1% globally.
— SS Innovations (NASDAQ: SSII) announced 200+ SSi Mantra systems deployed worldwide with 12,000+ procedures across 170 surgical indications; third-generation entrant pursuing affordability and telesurgery, signaling ecosystem diversification beyond tier-1 vendors targeting cost-conscious healthcare systems.
— Bielefeld University 10-year cohort (146 robotic, 93 laparoscopic) using propensity-score weighting showed robotic approach significantly reduced conversion (2.7% vs 15.1%, OR 0.15) and shortened post-operative stay (−4.72 days), demonstrating institutional de-risking benefits in rectal cancer.
— Dwight Meglan (25+ years surgical robotics expertise) documents critical reimbursement barrier: neither Medicare nor commercial payers pay premium for robotic vs laparoscopic surgery despite 10M+ cumulative U.S. procedures, with only 9% of 149 surgical-AI companies achieving independent economics—identifies structural adoption constraint.
— Le Nouvel Économiste healthcare economics analysis documents institutional-scale adoption failure: French public hospitals absorb full capital and consumable costs (€1-2.5M + maintenance) while receiving conventional surgery reimbursement, creating negative unit economics and structural ROI barrier absent territorial consolidation.
— Tungs' Taichung MetroHarbor Hospital (Taiwan) longitudinal case study (2012-2022) documented robotic adoption stages with biopsy-free surgery rising from 23.6% to 76.8% and pathological confirmation from 40% to 76.8%, showing organizational transformation (training, protocols, multidisciplinary workflows) as determinant of mature adoption.
— FDA De Novo authorization for Johnson & Johnson OTTAVA marks third major vendor entry into surgeon-assisted surgical robotics; table-integrated architecture approved for 10 general surgery indications including gastric bypass, gastrectomy, and cholecystectomy, signaling ecosystem maturity beyond da Vinci monopoly.
— First U.S. prospective trial of Medtronic Hugo RAS (137 patients, 6 centers) demonstrated 98.5% surgical success and met safety endpoints across prostatectomy (3.7% Clavien ≥III), cystectomy (17.9%), and nephrectomy (1.9%), validating competing-platform clinical parity with da Vinci.
— Phase 3 multicenter RCT (7 Chinese hospitals, 268 patients) showed robotic pancreatoduodenectomy achieved non-inferiority for functional recovery (12.1 vs 16.0 days) with reduced morbidity (31.1% vs 36.1%) but higher operative time and cost, demonstrating oncologic benefit at production-volume credentialed centers.